InsiderTrades

Form 4 for CELU Celularity Inc

Accepted 2026-04-15 16:30:25 ET · period of report 2026-04-13 · accession 0001493152-26-016834 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-04-15 16:30 2026-04-13 CELU Brigido Stephen Pres, Functional Regeneration M - OptEx $0.00 +821 9,742 +9% $0
D 2026-04-15 16:30 2026-04-13 CELU Brigido Stephen Pres, Functional Regeneration F - Tax $1.28 -268 9,474 -3% -$343.04
D 2026-04-15 16:30 2026-04-13 CELU Brigido Stephen Pres, Functional Regeneration M - OptEx $0.00 -821 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2026-04-13 M A 821 $0.00 9,742 D — — (F1) Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 3,281 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
2 Common Class A Common Stock 2026-04-13 F D 268 $1.28 9,474 D — — (F2) This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
3 Derivative Restricted Stock Units 2026-04-13 M D 821 $0.00 0 D — · — to — 821 Class A Common Stock (F3) Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. (F4) On April 13, 2022, the reporting person was granted 3,281 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4. (F4) On April 13, 2022, the reporting person was granted 3,281 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.